



1135

PTO:SB/21 08-00;


Approved for use through 10/31/02 OMB 0651 0031


U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	09/802,376	
	Filing Date	March 9, 2001	
	First Named Inventor	Gary Van NEST, et al.	
	Group Art Unit	1635	
	Examiner Name	J. Zara	
Total Number Of Pages In This Submission	5	Attorney Docket No.	377882001700

RECEIVED
FEB 20 2003
FBI CENTER 1600/2900

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input checked="" type="checkbox"/> Amendment / Reply	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declarations	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below)
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	<input type="checkbox"/> Return Postcard
<input type="checkbox"/> Information Disclosure Statement PTO Form 1449, References	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application	Remarks	 25225 PATENT, TRADEMARK OFFICE
<input type="checkbox"/> Response to Missing Parts under 37 C.F.R. 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY OR AGENT	
Firm or Individual Name	Karen R. Zachow, Registration No. 46,332 Morrison & Foerster LLP 3811 Valley Centre Drive, Suite 500, San Diego, California 92130
Signature	
Date	February 11, 2003

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"	
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231, on <u>2-16</u> 2003.	
 Rhea Amid	

Business Hours Statement: This form is required to be filed by the filer. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Issue Fee, Washington, D.C. 20231.



PATENT
Docket No. 377882001700

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to
Assistant Commissioner for Patents, Washington, D.C. 20231, on February 11, 2003.

Rhea Amd
Rhea Amd

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Gary VAN NEST and Stephen TUCK

Serial No.: 09/802,376

Filing Date: March 9, 2001

For: IMMUNOMODULATORY
FORMULATIONS AND METHODS
FOR USE THEREOF

Examiner: J. Zara

Group Art Unit: 1635

TECH CENTER 1600-2900

FEB 25 2003

RECEIVED

RESPONSE TO RESTRICTION REQUIREMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

This is in response to the Office Action dated January 24, 2003 (Paper No. 12) which sets forth a restriction requirement for pending claims 1-66 in the above-identified application. A response to this action is due February 24, 2003. Accordingly, this response is timely filed.

ELECTION OF INVENTION

In the pending Office Action, the restriction set forth in Paper No. 9, mailed October 3, 2002, is vacated and a new restriction requirement is set forth.

Claims 1-66 are pending in this application. Restriction has been required as between the following allegedly distinct groups of inventions:

Group I (claims 1-11 and 56-66): drawn to compositions comprising an IMP/MC complex; and

Group II (claims 12-55): drawn to methods of immune modulation.

Applicants traverse this restriction requirement on the grounds that the Examiner has not provided adequate support for the division of Groups I and II according to M.P.E.P. §§ 806.03; 806.04.

The separation of the claims of Groups I and II is allegedly supported with the statement that "the different inventions I and II are biologically and functionally different and distinct from each other." Office Action, page 3. Applicants respectfully disagree with this general statement. The product of the Group I claims is an immunomodulatory polynucleotide/microcarrier (IMP/MC) complex comprising a polynucleotide comprising an immunostimulatory sequence linked to a nonbiodegradable microcarrier. The claims of Group II are drawn to a method of modulating an immune response comprising administering an IMP/MC complex. Applicants request that the Examiner support the assertion that the product (Group I) and the method of using the product (Group II) are distinct inventions or withdraw the requirement to separate groups (M.P.E.P. §806.05(h)).

Further, Applicants respectfully traverse the classification differences of Groups I and II. For example, the classification definitions of the Office list compositions in class 435 as involving "immobilized or insolubilized enzyme or a test or culture media." Applicants submit that nothing in the claims leads one to classify the claims of Group I into class 435. Applicants request the Examiner explain the basis for distinguishing the classification of these two groups, when the claimed components are very similar.